Iovance Biotherapeutics has been granted a patent for an improved method of reprogramming tumor infiltrating lymphocytes (TILs) to create therapeutic populations with enhanced efficacy. The method involves multiple expansions of TILs using specific cell culture mediums and supplements, resulting in a modified population of TILs that can be used in therapeutic treatment regimens. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of September 2023 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for method of expanding therapeutic til populations
A recently granted patent (Publication Number: US11713446B2) describes a method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs. The method involves several steps to produce a population of TILs that can be used for therapeutic purposes.
The first step of the method involves obtaining a population of TILs from a tumor resected from a patient. These TILs are then cultured in a cell culture medium containing IL-2 for a period of about 3-14 days, resulting in a second population of TILs.
In the next step, the second population of TILs is further expanded by supplementing the cell culture medium with additional IL-2, OKT-3, and antigen presenting cells (APCs). This second expansion is performed for about 7-14 days, resulting in a third population of TILs. This third population of TILs is considered a therapeutic population.
Before or during the first expansion, second expansion, or after the second expansion, the TIL populations can be modified to transiently alter the expression of one or more proteins. This alteration can involve the insertion of nucleic acid molecules, such as RNA molecules, into the TIL populations. The nucleic acid insertion can be achieved through electroporation or microfluidic membrane disruption.
The proteins that can be altered include IL-2, IL-7, IL-10, IL-12, IL-15, and IL-21. The method allows for the alteration of one or more of these proteins to increase their expression. In some embodiments, a membrane-bound form of IL-2, IL-15, or IL-21 can be encoded by the inserted mRNA molecules.
The method also includes additional steps such as harvesting the therapeutic population of TILs, transferring them to an infusion bag, and cryopreserving the bag. The entire process, from the first expansion to the harvesting of TILs, can be performed within about 22 days. Furthermore, the method can be performed in a closed system.
This patented method provides a detailed and specific approach for expanding TILs into a therapeutic population. By altering the expression of specific proteins, the method aims to enhance the therapeutic potential of TILs for the treatment of tumors.
To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
